黄金城集团

至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

USP22 Deubiquitinates CD274 to Suppress Anticancer Immunity.

Cancer Immunol Res. 2019; 
Huang Xing,Zhang Qi,Lou Yu,Wang Junli,Zhao Xinyu,Wang Lin,Zhang Xiaozhen,Li Shanshan,Zhao Yulan,Chen Qi,Liang Tingbo,Bai X
Products/Services Used Details Operation
Proteins, Expression, Isolation and Analysis Protein samples of immunoprecipitation or cell lysates were further resolved by SDS-PAGE with 4-20% 15-well SurePAGETM Gel (M00657, GenScript), and then transferred onto nitrocellulose membrane (66485, PALL) following standardprocedures. Get A Quote

摘要

PD-1 (CD279)-PD-L1 (CD274) inhibitory signaling is critical for cancer immune evasion, and thus has become one of the major targets in anticancer immunotherapy. There are several studies that demonstrate the potent effects of posttranslational modifications of CD274 on immune inactivation and suppression, such as ubiquitination, phosphorylation, glycosylation, and palmitoylation. However, the regulatory mechanisms for CD274 deubiquitination are still largely unclear. Here, we identified ubiquitin-specific protease 22 (USP22) as a novel deubiquitinase of CD274. USP22 directly interacted with the C terminus of CD274, inducing its deubiquitination and stabilization. Across multiple cancer types, ... More

关键词